These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8110626)

  • 21. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
    Chan DC; Barrett HP; Watts GF
    Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
    Lankin VZ; Tikhaze AK; Kukharchuk VV; Konovalova GG; Pisarenko OI; Kaminnyi AI; Shumaev KB; Belenkov YN
    Mol Cell Biochem; 2003 Jul; 249(1-2):129-40. PubMed ID: 12956408
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipid-lowering medications for children and adolescents.
    Miller ML; Wright CC; Browne B
    J Clin Lipidol; 2015; 9(5 Suppl):S67-76. PubMed ID: 26343214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gemfibrozil in Combination with Statins-Is It Really Contraindicated?
    Wiggins BS; Saseen JJ; Morris PB
    Curr Atheroscler Rep; 2016 Apr; 18(4):18. PubMed ID: 26932225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure.
    Tziomalos K; Karagiannis A; Athyros VG
    Curr Pharm Des; 2014; 20(40):6306-13. PubMed ID: 24953388
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of a new hypolipemic preparation fluvastatin (Lescol) on rheological indices and hemostatic parameters].
    Filippova VG; Mantsurova AV; Zadionchenko VS; Zaporozhets TP
    Ter Arkh; 1997; 69(4):43-5. PubMed ID: 9213958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.
    Isles CG; Paterson JR
    QJM; 2000 Sep; 93(9):567-74. PubMed ID: 10984551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the effects of gemfibrozil and clofibric acid on peroxisomal enzymes and cholesterol synthesis of rat hepatocytes.
    Hashimoto F; Taira S; Hayashi H
    Biol Pharm Bull; 1998 Nov; 21(11):1142-7. PubMed ID: 9853402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism.
    Hashimoto F; Hamada S; Hayashi H
    Biol Pharm Bull; 1997 Apr; 20(4):315-21. PubMed ID: 9145201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Szostak WB
    Eur J Clin Pharmacol; 1991; 40(1):33-41. PubMed ID: 2060543
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-lowering agents for nephrotic syndrome.
    Kong X; Yuan H; Fan J; Li Z; Wu T; Jiang L
    Cochrane Database Syst Rev; 2013 Dec; (12):CD005425. PubMed ID: 24327265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial dyslipidaemias: an overview of genetics, pathophysiology and management.
    Hachem SB; Mooradian AD
    Drugs; 2006; 66(15):1949-69. PubMed ID: 17100406
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
    Murdock DK; Murdock AK; Murdock RW; Olson KJ; Frane AM; Kersten ME; Joyce DM; Gantner SE
    Am Heart J; 1999 Jul; 138(1 Pt 1):151-5. PubMed ID: 10385779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug treatment of combined hyperlipidemia.
    Wierzbicki AS; Mikhailidis DP; Wray R
    Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
    Tikkanen MJ; Helve E; Nikkilä EA
    Eur Heart J; 1987 Aug; 8 Suppl E():97-101. PubMed ID: 3315684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.